Full Text View
Tabular View
No Study Results Posted
Related Studies
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
This study has been completed.
Study NCT00203034   Information provided by Teva Pharmaceutical Industries

First Received on September 13, 2005.   Last Updated on March 8, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Additional conditions recognized in this trial
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Interventions listed in this trial
rasagiline mesylate
1.0 mg rasagiline mesylate
Placebo
Additional drug interventions recognized in this trial
Levodopa
Rasagiline
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Monoamine Oxidase Inhibitors
Neuroprotective Agents
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Teva Pharmaceutical Industries


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services